News and Events

NJ Bio, Inc. is excited to announce its participation in the BIO International Convention 2025, to be held from June 16-19, at the Boston Convention & Exhibition Center. It is one of the largest and most comprehensive events in the biotech industry, bringing...

NJ Bio, Inc., will be participating in the AACR Annual Meeting, taking place from April 25–30, 2025, at McCormick Place Convention Center, Chicago, Illinois. AACR, the largest conference in cancer research, brings together scientists, clinicians and professionals...

NJ Bio, Inc. is excited to announce its strategic partnership with Suven Pharmaceuticals, a leading CDMO based in Hyderabad, India. Suven, backed by Boston-based private equity firm Advent International, has acquired a 56% equity stake in NJ Bio through a $64.4...

NJ Bio, Inc., has been awarded the prestigious Best Contract Research Organization (CRO) title at the 11th Annual World ADC Awards in San Diego, marking the company's fourth consecutive win. This successive win underscores NJ Bio’s commitment and the continued trust...

NJ Bio, Inc., is excited to announce a new strategic collaboration with Charles River Laboratories (CRL) aimed at enhancing ADC manufacturing capabilities and accelerating the journey of ADC programs from the laboratory to the clinic. This partnership combines CRL’s...

NJ Bio, Inc. is thrilled to announce its participation in the BIO International Convention 2024, one of the largest and most comprehensive events in the biotech industry. The convention, scheduled from June 3-6, 2024, at the San Diego Convention Center, will host over 20,000 industry leaders from around the globe, offering a unique platform for networking, collaboration, and innovation. Attendees can look forward to a wide array of sessions and exhibits focused on the latest research and emerging technologies in the biotech sector.

NJ Bio, Inc., is thrilled to announce its participation in several prestigious conferences this year. Starting the year with a strong presence, NJ Bio will be participating in the renowned AACR Annual Meeting, a premier event in cancer research and medicine. Scheduled...

NJ Bio, Inc., is delighted to announce its recent honor as the recipient of the “Best Contract Research Organization” (CRO) Award at the 10th Annual World ADC Awards. The award serves as a testament to NJ Bio's unwavering commitment to delivering innovative solutions...

NJ Bio, Inc., took the global stage at the 14th Annual World ADC conference, shedding light on a prevalent challenge in the world of Antibody-Drug Conjugates (ADCs). The issue at hand: the replication of ideas (or as we term it the “copy-paste” approach) and a...

NJ Bio, Inc., had the privilege of hosting Senior Vice President, Head of Biologics & Biotherapeutics at Exelixis, Inc., Dr. Seema Kantak, at our headquarters in Princeton.

The World ADC Awards is a platform that acknowledges creativity, innovation, leadership and devotion in the field of antibody-drug conjugates. This year Hanson Wade is back with the 10th Annual ADC Awards, celebrating a decade of honoring the very best in the field....

NJ Bio is thrilled to share that the Honorable Ms. Kiran Mazumdar Shaw inaugurated the “Center for NMR Excellence” equipped with the state-of-the-art JEOL 800 MHz and Bruker 700MHz NMR spectrometers at our Princeton headquarters. Kiran Mazumdar Shaw, a renowned...

NJ Bio, Inc. is extremely grateful to Professor Vivek Gupta, Chairperson of the AAPS Discussion Group, and the NERDG committee for inviting our President & CEO, Dr. Naresh Jain, as a keynote speaker at the 25th Annual AAPS NERDG Conference. It was an honor to be...

NJ Bio, Inc. was pleased to welcome Dr. Yutaka Matsuda and his colleague Mr. Hiroki Imai (Business Development Manager) from Ajinomoto Bio-Pharma Services to our headquarters in Princeton. Dr. Yutaka Matsuda is a double Ph.D. and an expert in site-specific chemical...

NJ Bio, Inc., had the great honor to welcome their esteemed SAB member, Fellow of The American Institute for Medical and Biological Engineering (AIMBE) and renowned biotechnology consultant, Dr. Ravi Chari, to their headquarters in Princeton, New Jersey in January...

NJ Bio, Inc. enters into a global license and assignment agreement with Aarvik Therapeutics Inc., to develop next-generation ADCs using their novel class of payloads and Aarvik’s innovative therapeutic antibodies. In the recently finalized agreement, Aarvik...

On 29th November 2022, NJ Bio, Inc., had the distinct pleasure of welcoming a good friend and mentor, Dr. Thomas (Tom) Nittoli from Regeneron Pharmaceuticals, Inc. to share his views on advancing conjugated antibodies and proteins from discovery to development of...

On November 9th and 10th, 2022, NJ Bio, Inc. hosted two esteemed ADC researchers, Dr. Jagath Reddy Junutula, President, CEO, and Co-founder of Aarvik Therapeutics Inc. and Dr. Brian Mendelsohn, Executive Director, Antibody Drug Conjugates at Exelixis, Inc....

NJ Bio, Inc. was proud to be a program partner at 5th Annual TPD Summit held in Boston between October 25 – 28, 2022. Our distinguished research leader, David C. Fry, Ph.D. was an expert speaker at the event. Dr. Fry has expertise in NMR analysis of proteins,...

NJ Bio, Inc. was awarded the 9th Annual World ADC Award for Best Contract Research Provider category at the 13th Annual World ADC Conference 2022 held in San Diego. Through the years, the Annual World ADC Awards recognizes innovation, and leadership within the...

Over the years, NJ Bio, Inc. has stayed committed to the Antibody Drug Conjugates (ADCs) field by sponsoring several distinguished events in this space and has dedicated itself to educating the global community about this emerging area of innovation. We received yet...

NJ Bio is thrilled to be a Senior Partner and Sponsor at the 13th World ADC Conference to be held in San Diego, California on September 6-9, 2022. The World ADC Conference is the most comprehensive and longest standing Antibody-Drug Conjugate Conference that provides...

PRINCETON, N.J.--(BUSINESS WIRE)--NJ Bio is procuring an 800 MHz NMR spectrometer with a cryogenic probe from JEOL. As part of this collaboration, NJ Bio will contribute its expertise in antibody drug conjugates, oligonucleotide conjugates, and other chemistries to...

Princeton, NJ – NJ Biopharmaceutical (d/b/a NJ Bio), a global provider of outsourced integrated chemistry and biology services to clients in the pharmaceutical and biotechnology industries was awarded the Best Contract Research Provider Award, 2021 at the 8th Annual...

NJ Biopharmaceuticals LLC (d/b/a NJ Bio), an expert provider of chemistry and biopharmaceutical services welcomed the appointments of Ilan Kaufthal as Senior Advisor, and Ronald Gold, Steven Klosk, and Chetan Jain to its Board of Directors. Ilan, Ron, Steve and Chetan...

NJ Bio, an expert in bioconjugation, nucleotide chemistry, custom synthesis, flow chemistry and process development, and application of BioNMR to drug discovery programs, is moving to new, state-of-the-art headquarters in Princeton, NJ.

NJ Bio has published a review article on Antibody-Oligonucleotide Conjugates. Dugal-Tessier, J.; Thirumalairajan, S.; Jain, N. Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates. J. Clin. Med 2021,10, 838. https://doi.org/10.3390/jcm10040838...

North Brunswick, NJ and Bristol, PA — NJ Biopharmaceuticals LLC (d/b/a NJ Bio), a CRO providing integrated chemistry and biology services, was awarded Runner Up in the Best Contract Research Provider category at the 7th Annual World ADC Awards. The Best CRO Provider...

NJ Bio would like to share that Dr. Naresh Jain, NJ Bio’s President & CEO, and Dr. Julien Dugal-Tessier, NJ Bio’s Director of Innovative Chemistry and Innovation, will hold a Workshop at the 10th Annual World ADC London 2020. The workshop will be titled “The...